Sarep­ta shakes up C-suite as they pre­pare to test FDA on Duchenne again

Af­ter slow­ly los­ing ex­ec­u­tives over the last two years, Sarep­ta has an­nounced a host of changes at its high­est lev­el.

Sarep­ta on Mon­day an­nounced a new CFO, chief com­mer­cial of­fi­cer, CSO and gen­er­al coun­sel, ef­fec­tive­ly giv­ing the biotech a new C-suite in a sin­gle press re­lease.

Sud­den and sweep­ing ex­ec­u­tive changes aren’t gen­er­al­ly a great in­di­ca­tor for a com­pa­ny’s health, but the cir­cum­stances around Sarep­ta’s lat­est changes are rel­a­tive­ly unique. The com­pa­ny hasn’t had a CSO since 2018, when Guriq Basi de­part­ed af­ter a one-year tenure. Their long­time chief com­mer­cial of­fi­cer, Bo Cum­bo, re­cent­ly spun out on his own, rais­ing $107 mil­lion for a new gene ther­a­py play. And their long­time CFO and CBO Sandy Ma­hatme “re­tired” in June for what turned out to be an op­por­tu­ni­ty to help run Bob Nelsen’s $800 mil­lion start­up Re­silience.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.